Starting patients on the V-Go Disposable Insulin Delivery Device - A simple guide for your practice - For adult patients with Type 2 diabetes on ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Starting patients on the V-Go®
Disposable Insulin Delivery Device
A simple guide for your practice
For adult patients with Type 2 diabetes
on basal insulin who need to take the next step
Identify appropriate candidates
Add prandial control with V-Go®
Ideal patients to start on V-Go
Elevated A1C
(A1C ≥8%)1
Basal insulin dose After 12 weeks
≥30 U/day of basal insulin
or ≥0.5 U/kg2,3 titration4-6
Patients who may not be appropriate for V-Go
Patients who have to make regular adjustments or modifications to their basal
rate during a 24-hour period, or whose amount of insulin used at meals requires
adjustments of less than 2-Unit increments, should not use V-Go as it may result
in hypoglycemia.
See the V-Go Instructions for Patient Use (Section 3) for the Indication, Warnings,
and other safety information for V-Go.
2
Start V-Go: 3 easy steps
1. Write
prescriptions for V-Go and insulin*
2. Ensure
patients know how to use V-Go
Direct
3. patients to call
Valeritas Customer Care (VCC)
*A U-100 fast-acting insulin should be used with V-Go. Humalog®
(insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin)
have been tested by Valeritas, Inc. and found to be safe for use in V-Go.
Humalog is a registered trademark of Eli Lilly and Company.
NovoLog is a registered trademark of Novo Nordisk A/S.Meet patient needs
with 3 V-Go® options
*
*
*
*You can only click the Bolus Delivery Button 18 times in every 24-hour period.
Each click of the Bolus Delivery Button delivers 2 Units of insulin (1 click = 2 Units).
A co-pay reduction card is available
for commercially insured patients.
Download it at www.go-vgo.com/co-pay-card.
4Get patients started
with 2 prescriptions
V-Go
Select the appropriate V-Go option
Rx: V-Go
Size: 20 U, 30 U, 40 U
Package size: Each
Sig:
NDC:
Use 1 V-Go for
24 hours as directed V-Go 20: 08560-9400-03
Disp: #30 V-Go 30: 08560-9400-02
Dosage form: Device V-Go 40: 08560-9400-01
Insulin
U-100 fast-acting insulin*
—2 vials for V-Go 20 Example:
—3 vials for V-Go 30 For V-Go 30 insulin eRx
and V-Go 40
Sig: Inject subcutaneous daily.
Click on Humalog Disp: #3 x 10 mL vials required
or NovoLog per month for use in V-Go 30.
Total daily dose will vary.
Click unstructured and Pharmacy Per FDA labeling, V-Go 30
type in the Sig, Disp, notes: requires 3 vials of insulin
and Pharmacy notes per month.
*A U-100 fast-acting insulin should be used with V-Go. Humalog®
(insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin)
have been tested by Valeritas, Inc. and found to be safe for use in V-Go.
Humalog is a registered trademark of Eli Lilly and Company.
NovoLog is a registered trademark of Novo Nordisk A/S.V-Go® dosing—Initiate
Goal: Reach 50/50 split on the daily basal-bolus insulin dose3,7
Adults on basal insulin only (± OADs)3,8
Patient’s
body weight
≤220 lb >220 lb
x 0.45 kg/lb x 0.5 U/kg
Basal rate Basal rate
V-Go 20 V-Go 30
Units/24 hours Units/24 hours
Bolus dosing Bolus dosing
2 clicks/meal 3 clicks/meal
1 click = 2 Units 1 click = 2 Units
When appropriate, consider advising patients to click when they snack.
Ensure that your patients have a plan to manage hypoglycemia and hyperglycemia.
6V-Go dosing—Titrate
Goal: Reach 50/50 split on the daily
basal-bolus insulin dose3,7
Improving postprandial glucose can help reduce fasting and preprandial
glucose levels and improve control.9-13
As with any insulin therapy:
Titration with V-Go is critical to improving glycemic control.
First optimize bolus Adjust basal if needed
After optimizing bolus dosing,
If mealtime blood glucose is
increase the V-Go option if
consistently not at goal, add
A1C is not at goal or fasting
clicks weekly until optimized
glucose is still elevatedMake sure patients know how to use V-Go® Easy to fill Patients fill a new V-Go with insulin each day. Easy to apply Patients simply place V-Go on their skin and press the Needle Button to start the basal rate. Easy to use Patients use the Bolus Ready Button and Bolus Delivery Button at mealtimes. (1 click = 2 Units) For the simple steps on how to fill, apply, and use V-Go, refer to the print, interactive, or video versions of the Quick Reference Guide at www.go-vgo.com. Ensure that patients understand basal-bolus therapy and that they have a plan to manage hypoglycemia and hyperglycemia. 8
Direct patients to enroll
in Valeritas Customer Care (VCC)
Comprehensive benefits for you and your patients, including a 1:1 partnership
with a dedicated representative and 24/7 support at 1-866-881-1209.
Benefits for your
Benefits for you
patients
Decreases call frequency to
Responds to V-Go
24/7 assistance your office and offers patient
questions live anytime
support after hours
Provides expert personalized Fewer phone calls
Reimbursement
insurance guidance and and contacts with
help
benefits investigation insurance companies
Makes obtaining V-Go Patients easily get
and using the Pharmacy support the product you
co-pay card easy prescribe for them
Provides initial instruction Lessens staff time needed
plus follow-up to help V-Go use to show patients how to fill,
patients succeed with V-Go apply, and use V-Go
Keep your patients on track Promote patient compliance
with regular calls over the Follow-up calls while reducing the need
first 90 days for office follow-up
Provides online access to V-Go LifeTM Helps keep patients
practical information about Self-Management motivated and encourages
diabetes and V-Go Program compliance
Valeritas does not give medical advice about insulin therapy.
Patients should discuss all medical therapies with you
and follow your instructions.Take the next step
V-Go® delivers a continuous
preset basal rate of insulin
plus on-demand bolus
dosing at mealtimes,
which may help improve
glycemic control.9,14-16
10Notes
3 easy steps to starting your
patients on V-Go®
1. Write
prescriptions for V-Go and insulin*
2. Ensure
patients know how to use V-Go
Direct
3. patients to call
Valeritas Customer Care (VCC)
We’re here 24/7
You and your patients can find help day or night.
Call 1-866-881-1209 or visit www.go-vgo.com.
Important Risk Information:
If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if
the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go
Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during
insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other
adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at
the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.
*A U-100 fast-acting insulin should be used with V-Go. Humalog® (insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin) have been tested by
Valeritas, Inc. and found to be safe for use in V-Go.
References: 1. Nathan DM, et al. Diabetes Care. 2009;32(1):193-203. 2. Inzucchi SE, et al. Diabetes Care. 2012;35(6):1364-1379. 3. Edelman SV,
et al. Diabetes Technol Ther. 2010;12(8):627-633. 4. Strange P. J Diabetes Sci Technol. 2007;1(4):540-548. 5. Riddle MC, et al. Diabetes Care.
2003;26(11):3080-3086. 6. In the treat-to-target study. http://www.lantus.com/hcp/about-lantus/vs-nph-efficacy. Accessed September 24, 2014.
7. Bode BW, et al. Diabetes Metab Res Rev. 2002;18(suppl 1):S14-S20. 8. Data on file. Valeritas, Inc. 9. Kapitza C, et al. J Diabetes Sci Technol.
2008;2(1):40-46. 10. Holman RR, et al. N Engl J Med. 2007;357(17):1716-1730. 11. Holman RR, et al. N Engl J Med. 2009;361(18):1736-1747.
12. Woerle HJ, et al. Diabetes Res Clin Pract. 2007;77(2):280-285. 13. Riddle M, et al. Diabetes Care. 2011;34(12):2508-2514. 14. Grunberger G,
et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress; May 14-18, 2014;
Las Vegas, NV. Abstract 224. 15. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 16. Omer A, et al. Poster presented at:
American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL. Abstract 980-P.
V-Go is a registered trademark of Valeritas, Inc.
12
ART-712 Rev: A 09/2014 © 2014 Valeritas, Inc.You can also read
